Log in to your Inderes Free account to see all free content on this page.

Thor Medical

Less than 1K followers

TRMED

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

Thor Medical is a manufacturer and supplier of alpha particle emitters for cancer treatment. Radionuclide therapy (RNT) or radioligand therapy (RLT) using alpha particle emitters is a promising technology for cancer treatment. The main focus of the company is to refine the production technology, secure the customer base and necessary regulatory approvals for industrialization. Thor Medical is headquartered in Oslo.

Market cap

-

Turnover

-

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

26.2.

2026

Annual report '25

23.4.

2026

General meeting '26

All

Press releases

ShowingAll content types

Regulatory press release12/4/2025, 7:00 AM

TRMED: RadioMedix and Thor Medical enter supply agreement for thorium-228

Press release11/28/2025, 7:39 AM

BioStock: Thor Medical advances toward commercial scale following pilot success and major deal streak

Regulatory press release11/20/2025, 12:27 PM

Thor Medical ASA - New share capital registered

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release11/20/2025, 6:30 AM

TRMED: Thor Medical enters supply agreement with NucliThera for thorium-228

Regulatory press release11/18/2025, 6:30 AM

TRMED: Thor Medical strengthens executive team to realise leadership ambitions in targeted alpha therapies

Regulatory press release11/11/2025, 10:15 PM

Thor Medical - Issuance of RSU shares to members of the board

Press release11/7/2025, 7:14 AM

BioStock: Thor Medical comments on the Telix agreement

Regulatory press release11/6/2025, 6:30 AM

TRMED: Thor Medical and Telix Pharmaceuticals sign strategic supply agreement for thorium-228

Regulatory press release8/29/2025, 5:15 AM

Thor Medical ASA interim results for 1H 2025 - strong operational and commercial progress

Regulatory press release8/29/2025, 5:00 AM

TRMED: Thor Medical and Oncoinvent Enter Strategic Thorium-228 Supply Agreement

Regulatory press release8/22/2025, 6:00 AM

Invitation to presentation of Thor Medical ASA's 1H 2025 on Friday 29 August at 08:00

Regulatory press release8/4/2025, 5:30 AM

TRMED: Thor Medical and AdvanCell expand strategic supply agreement for Thorium-228

Regulatory press release8/1/2025, 6:58 AM

Thor Medical ASA - Share capital increase in relation to Subsequent Offering is registered

Regulatory press release7/4/2025, 8:41 AM

Thor Medical ASA: Final results of the Subsequent Offering

Regulatory press release7/3/2025, 5:00 AM

Thor Medical ASA: The Subscription Period in the Subsequent Offering ends at 16:30 CEST today

Regulatory press release6/26/2025, 12:33 PM

Thor Medical ASA: Primary insider notification and disclosure of large shareholdings

Regulatory press release6/26/2025, 12:24 PM

Thor Medical ASA - Share capital increase in relation to the Private Placement and the PrimaryBid Offering is registered

Regulatory press release6/26/2025, 5:00 AM

Thor Medical ASA: Commencement of the subscription period for the subsequent offering

Regulatory press release6/25/2025, 4:58 PM

Thor Medical ASA: Registration of national prospectus and launch of subsequent offering

Regulatory press release6/19/2025, 5:30 AM

Thor Medical ASA: Ex. right to participate in subsequent offering today

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.